Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
47.37
-0.26 (-0.55%)
Feb 21, 2025, 4:00 PM EST - Market closed
Merus Employees
As of December 31, 2023, Merus had 229 total employees, including 172 full-time and 57 part-time employees. The number of employees increased by 8 or 3.62% compared to the previous year.
Employees
229
Change (1Y)
8
Growth (1Y)
3.62%
Revenue / Employee
$156,908
Profits / Employee
-$1,067,930
Market Cap
3.24B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
MRUS News
- 4 days ago - Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma - GlobeNewsWire
- 9 days ago - Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - GlobeNewsWire
- 17 days ago - New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer - GlobeNewsWire
- 4 weeks ago - Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff - Seeking Alpha
- 5 weeks ago - Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs - GlobeNewsWire
- 2 months ago - Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - GlobeNewsWire
- 2 months ago - Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC - GlobeNewsWire
- 2 months ago - Merus Scores Its First FDA Approval For Lung Cancer Drug - Benzinga